TDC
CBIO

Thompson Davis & Co’s Crescent Biopharma CBIO Stock Holding History

Thompson Davis & Co’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$18K Hold
13
– – 0.04% 351
2018
Q2 		$20K Hold
13
– – 0.05% 312
2018
Q1 		$20K Hold
13
– – 0.05% 293
2017
Q4 		$21K Buy
13
+5
+63% +$6.61K 0.05% 317
2017
Q3 		$10K Buy
+8
New +$9.39K 0.02% 683

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thompson Davis & Co's CBIO Position: Q3 2018 in Review

Thompson Davis & Co held its Crescent Biopharma (CBIO) position steady in Q3 2018 at 13 shares worth $18K. The position accounts for 0.04% of the portfolio, ranked #351.

Thompson Davis & Co first reported a position in CBIO in Q3 2017 and has held it in 5 quarters since. The position peaked at $21K in Q4 2017. 85 funds tracked by Wall St. Rank hold CBIO as of Q3 2018.

  • Thompson Davis & Co held 13 shares of Crescent Biopharma worth $18K as of Q3 2018.
  • Thompson Davis & Co left its Crescent Biopharma share count unchanged in Q3 2018.
  • Crescent Biopharma made up 0.04% of Thompson Davis & Co's portfolio in Q3 2018, its #351 holding.
  • Thompson Davis & Co first reported a position in Crescent Biopharma in Q3 2017 and has held it in 5 quarters since.
  • Thompson Davis & Co's Crescent Biopharma position peaked at $21K in Q4 2017.
  • 85 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.